Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences Co., Ltd. has announced the acceptance of their Investigational New Drug application for JS125, a novel targeted treatment for malignant tumors. The drug, developed in collaboration with Wigen Biomedicine Technology, has potential as an epigenetic modulator and aims to treat cancer by various mechanisms including cell cycle blockage and promoting tumor cell death. The company cautions investors about the inherent risks associated with pharmaceutical development and pledges to keep stakeholders informed on the project’s progress.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.
